Back

Atrogi's ATR-258 shows approximately 13% muscle-power improvement in 8-week study

Verifying
  • Atrogi reported positive human data for its lead candidate ATR-258.
  • 13% was the approximate improvement in lower-extremity muscle power from baseline.
  • Atrogi plans to initiate a Phase 2 trial in 2027, the company said.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Atrogi's ATR-258 shows approximately 13% muscle-power improvement in 8-week study - CoinPost Terminal